Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

References for PMC Articles for PubMed (Select 23467459)

1.

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

Hardy-Bessard AC, Delva R, Pivot X, Espié M, Dalenc F, Coulon Sfairi MA, Monnier A, Serin D, Veyret C, Lortholary A, Pavlyuk M, Kockler L, Pierga JY.

Bull Cancer. 2012 Jun;99(6):609-18. doi: 10.1684/bdc.2012.1586. French.

PMID:
22665515
2.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group.

Lung Cancer. 2012 Jun;76(3):362-7. doi: 10.1016/j.lungcan.2011.12.005. Epub 2012 Jan 14.

3.

Bevacizumab in non-small-cell lung cancer: a review.

Planchard D.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1163-79. doi: 10.1586/era.11.80. Review.

PMID:
21916570
4.

Safety of bevacizumab in patients with metastatic breast cancer.

Hamilton EP, Blackwell KL.

Oncology. 2011;80(5-6):314-25. doi: 10.1159/000328757. Epub 2011 Jul 19. Review.

PMID:
21778772
5.

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L.

Br J Cancer. 2011 Jun 28;105(1):58-64. doi: 10.1038/bjc.2011.201. Epub 2011 Jun 14.

6.

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J.

J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.

7.

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.

Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL.

J Clin Oncol. 2009 Oct 20;27(30):4966-72. doi: 10.1200/JCO.2008.21.6630. Epub 2009 Aug 31.

8.

Adverse events in bevacizumab and chemotherapy: patient management.

Blowers E, Hall K.

Br J Nurs. 2009 Apr 9-22;18(7):424-8. Review.

PMID:
19373187
9.

Managing adverse events in the use of bevacizumab and chemotherapy.

Blowers E, Hall K.

Br J Nurs. 2009 Mar 26-Apr 8;18(6):351-6, 358. Review.

PMID:
19329899
10.

Perforated colonic diverticular disease: the importance of NSAIDs, opioids, corticosteroids, and calcium channel blockers.

Piekarek K, Israelsson LA.

Int J Colorectal Dis. 2008 Dec;23(12):1193-7. doi: 10.1007/s00384-008-0555-4. Epub 2008 Aug 5.

PMID:
18679693
11.

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200.

J Clin Oncol. 2007 Apr 20;25(12):1539-44.

12.

Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?

Kabbinavar FF, Ellis LM.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S69-73. Review.

PMID:
15479482
13.

Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease.

Morris CR, Harvey IM, Stebbings WS, Speakman CT, Kennedy HJ, Hart AR.

Br J Surg. 2003 Oct;90(10):1267-72.

PMID:
14515298
14.

Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo.

Weltermann A, Wolzt M, Petersmann K, Czerni C, Graselli U, Lechner K, Kyrle PA.

Arterioscler Thromb Vasc Biol. 1999 Jul;19(7):1757-60.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk